YAZAN NUMAN, MD
Hematology & Oncology Physician · ORLAND PARK, IL
Individual Active NPI 1801243738
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 636 | 155,691 | $15,676,388 | $4,118,276 | $3,277,735 |
| 2023 | 436 | 80,728 | $9,478,059 | $2,271,449 | $1,806,100 |
| 2022 | 102 | 14,804 | $1,166,656 | $270,620 | $215,589 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 19,000 | $56 | $45 |
| J1453 | Injection, fosaprepitant, 1 mg | 17,250 | $0 | $0 |
| J9263 | Injection, oxaliplatin, 0.5 mg | 15,202 | $0 | $0 |
| J9075 | Injection, cyclophosphamide, not otherwise specified, 5 mg | 5,700 | $1 | $1 |
| J0897 | Injection, denosumab, 1 mg | 4,980 | $26 | $21 |
| J9267 | Injection, paclitaxel, 1 mg | 4,823 | $0 | $0 |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 3,290 | $4 | $4 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 2,668 | $0 | $0 |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,640 | $20 | $16 |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 2,640 | $20 | $16 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 2,320 | $0 | $0 |
| J2469 | Injection, palonosetron hcl, 25 mcg | 2,210 | $1 | $1 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Hematology & Oncology Physician | 207RH0003X | ✓ | 036.148703 | IL |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- Yes
Other Hematology & Oncology Physician providers in Illinois
- NPI 1033526165
- NPI 1427339928
- NPI 1376317388
- NPI 1598750101
- NPI 1528231750
- NPI 1548668148
- NPI 1871239582
- NPI 1912535188
See all Hematology & Oncology Physician providers in Illinois →
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.